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IN BRIEF 
 
Pearson et al. describe the structure 
guided discovery of benzothiazole N-
oxide PLK1 inhibitors that bind 
covalently with C67 through 
Meisenheimer complexes. These 
represent prototypes to exploit this 
unique mechanism of inhibition in drug 
discovery to achieve high specificity and 
still bind reversibly. 
 
 
 
 
 
 
 
HIGHLIGHTS 
 Identification of potent and selective PLK1 inhibitors via a structure-guided approach 
 Covalent binding with Cys67 of PLK1 occurs through a Meisenheimer complex (MC) residue in 
inhibition 
 Lack of activity against PLK1 C67S confirmed the role of this residue in inhibition 
 Lack of activity against PLK1 C67S confirmed the role of this residue in inhibition 
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SUMMARY  
The polo kinase family are important oncology targets that act in regulating entry into and progression 
through mitosis. Structure-guided discovery of a new class of inhibitors of PLK1 catalytic activity that 
interact with Cys67 of the ATP binding site is described. Compounds containing benzothiazole N-oxide 
scaffold not only bind covalently to this residue but are reversible inhibitors through the formation of 
Meisenheimer complexes. This mechanism of kinase inhibition results in compounds that can target PLK1 
with high selectivity while avoiding issues with irreversible covalent binding and interaction with other 
thiol containing molecules in the cell. Due to renewed interest in covalent drugs and the plethora of potential 
drug targets, these represent prototypes for the design of kinase inhibitory compounds that achieve high 
specificity through covalent interaction and yet still bind reversibly to the ATP cleft, a strategy that could 
be applied to avoid issues with conventional covalent binders. 
 
INTRODUCTION 
The polo like kinases are serine/threonine protein kinases that are key regulators of the cell cycle and in 
mammals have been reported to play numerous roles in regulating entry into and progression through 
mitosis (Craig et al., 2014; McInnes and Wyatt, 2011). PLK1 is expressed throughout the cell cycle although 
its activity peaks late in G2 and is sustained through mitosis (Hamanaka et al., 1995; Lee et al., 1995).  At 
the end of G2, through phosphorylation and promotion of nuclear translocation(Toyoshima-Morimoto et 
al., 2002), PLK1 acts on Cdc25C(Roshak et al., 2000), resulting in activation of CDK1/cyclin B by removal 
of inhibitory phosphate groups (Nurse, 1990). PLK1 also promotes sister chromatid separation mediated by 
activation of the APC(Golan et al., 2002; Kotani et al., 1998), and also through phosphorylation of the 
SCC1 subunit of cohesin  (Alexandru et al., 2001; Sumara et al., 2004). Mitotic exit occurs after PLK1 
interacts with and phosphorylates the kinesin-like protein, CHO1/MKLP-1 and promotes cytokinesis(Lee 
et al., 1995). Four closely related PLKs exist in humans(Glover et al., 1998) and structurally contain two 
separate, highly homologous domains: an amino-terminal region which contains the catalytic kinase domain 
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and a carboxy terminal domain that have two conserved polo-box regions  (Elia et al., 2003a; Elia et al., 
2003b) (one in  PLK4(Leung et al., 2002)). A fifth PLK has been identified but shown to lack a kinase 
domain(de Carcer et al., 2011). The polo boxes function in recruitment for subcellular localization and 
compartmentalisation(Lee et al., 1998). Furthermore there is evidence suggesting that the Polo-Box Domain 
(PBD) participates in regulating interactions with substrates e.g. Cdc25C phosphatase(Elia et al., 2003a; 
Elia et al., 2003b), as an autoregulatory domain(Jang et al., 2002). Furthermore, PBD-dependent PLK1 
activity is required for proper metaphase/anaphase transition and cytokinesis(Seong et al., 2002; Yuan et 
al., 2011).  
Over-expression of PLK1 is a common occurrence in cancer and is of prognostic value for several tumor 
types  (Knecht et al., 1999; Takahashi et al., 2003; Tokumitsu et al., 1999; Wolf et al., 1997; Yuan et al., 
1997). In addition, constitutive expression of PLK1 in mammalian cells can lead to malignant 
transformation  (Smith et al., 1997). PLK1 has been extensively validated as an anti-tumor drug-target using 
a variety of cellular and in vivo studies.  Downregulation of PLK1 activity through the administration of 
antisense oligonucleotides and siRNA molecules, have been demonstrated to be highly effective in 
inhibition of proliferation of cancer cells both in vitro and in vivo (Elez et al., 2000; Elez et al., 2003; 
Spankuch-Schmitt et al., 2002a; Spankuch-Schmitt et al., 2002b). Several drug candidates have been 
investigated clinically including BI2536 and GSK461364A with the most advanced compound being 
Volasertib (BI-6727), which is currently in a phase III trial, having recently been shown to have efficacy in 
combination with cytarabine in acute myeloid leukemia (Dohner et al., 2014; Gjertsen and Schoffski, 2014). 
Although promising activity has been observed, there is continued scope to improve clinical outcomes 
through optimization of mechanism of inhibition and pharmacokinetic and dynamic properties.  
Here a structure-guided design approach to the discovery and development of benzothiazole N-oxide 
PLK1 inhibitors is described. These highly selective molecules inhibit the enzyme through a covalent but 
reversible mechanism involving a Meisenheimer complex, that is without precedent in the protein kinase 
literature. In recent years, covalent inhibition of drug targets and especially of protein kinases has been 
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recognized as an effective approach to improving selectivity and for overcoming drug resistance, however 
is not without significant issues including potential toxicities (Baillie, 2016).  Inhibition through 
Meisenheimer complex formation is a promising strategy to combine the benefits of a covalent mechanism 
while retaining reversible binding to the drug target of interest. A recent report described the observation 
of a Meisenheimer complex in the context of nitrobenzothiazinone anti-tuberculosis drugs however did not 
elaborate these as contributing to potency and selectivity but merely from the standpoint of the metabolic 
implications for continuing development of this important class of drugs (Kloss et al., 2017). The 
compounds described herein therefore represent prototypes and proof of concept for exploiting the 
Meisenheimer complex in kinase inhibition and potentially more broadly in drug discovery. 
 
 
Figure 1. Chemical structures of PLK1 inhibitory compounds (2TA, 1; 5TA, 2, and adenosine 3) used in 
validation of homology model and for probing the covalent modification of the ATP binding site. 
 
 
 
RESULTS 
 PLK1 is irreversibly and selectively inhibited by thiol modifying agents 
A structure-guided approach for the discovery of the cyclapolin benzothiazole N-oxide class of 
inhibitors has been described (McInnes et al., 2006). This approach preceded the determination of the 
crystal structure of PLK1 KD. Upon construction of this homology structure and examination of the ATP 
binding site residues, it was observed that PLK1 had some unusual features compared to other protein 
kinases. In particular, the residue at the end of the glycine-rich loop that commonly interacts with the ribose 
of ATP and is frequently a valine, occurs as a cysteine in PLK1 (C67). This residue in other protein kinase-
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ligand crystal structures generally makes significant contacts with ATP competitive small molecules (e.g 
V18 in CDK2). The unique characteristic of C67 in PLK1 thus could allow exploitation of the nucleophilicity 
of the thiol side chain to enable covalent binding of PLK1 inhibitors.  
The development of irreversible kinase inhibitors has precedent in the literature in the context of the 
EGFR tyrosine kinases, where non-covalently binding ATP competitive compounds were converted by 
addition of a geometrically appropriate reactive functionality (Singh et al., 1997). These compounds were 
designed to form a covalent bond with a cysteine in the kinase active site and thus to take advantage of the 
thiol attack on the inhibitor. In the erbB1 kinase domain, 2’-thioadenosine (2TA), 1 (Figure 1) places the 
thiol adjacent to the C833 and was shown in this to form a disulphide bond and to inhibit to inhibit the kinase 
activity.   As the active site cysteine (C67) is on the opposite face of the ATP cleft in the PLK1 context, 
inhibition would necessitate the synthesis of 5’-thioadenosine (5TA), 2 (Figure 1) so as to position the 
ribose thiol proximal to the reactive side chain. Flexible docking of 5TA, 2 with PLK1 was completed and 
the binding mode was verified through comparison with ATP bound crystal structures. Further to this, the 
disulfide link between C67 and 5TA, 2 was formed in silico and resulted in a conformation (Figure 2) similar 
to the experimental binding mode observed in other kinases. Subsequent to this, 2 was synthesized and 
shown to inhibit PLK1 kinase activity with an IC50 of 39 M. 2TA, 1 exhibited markedly lower inhibition 
(120 M) and adenosine, 3 (Figure 1), itself had no observed activity against PLK1 (> 200 M).  
Discovery of Potent and Selective inhibitors of PLK1 using Lidaeus 
The homology model generated for the kinase domain of PLK1 was validated through the observed 
correlation of intermolecular contacts and binding energies of discovered pyrimidine inhibitors and through 
the assay results obtained from the use of thiol modifying agents. Since it was considered to be of sufficient 
computational reliability, the model structure was further used in high-throughput docking calculations to 
predict potential novel PLK1 starting points. In order to carry out this task, one of the previously docked 
thiazole anilino-pyrimidine compounds in complex with PLK1 was used as a template structure for Lidaeus 
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 Figure 2. Complex of 5TA, 2 with the 
ATP binding site of PLK1. This model was 
generated through flexible docking of the free 
thiol compound into the PLK1 homology 
model with selected conformations that 
correspond to the known binding mode of 
ATP derivatives with kinases. The irreversible 
inhibition of this derivative is supported by the 
formation of the disulfide linkage in silico and 
minimization of the covalently linked 
inhibitor 
 
calculations. Lidaeus (Taylor et al., 2008; Wu 
et al., 2003), a tool for rapid flexible docking 
of ligands into protein binding sites, generates 
site points from energies of probe atoms 
within a specified radius of the inhibitor. Interatomic ligand vectors are then matched with the site points 
from fragments of the molecule followed by positioning of subsequent fragments and ranking by overall 
intermolecular energy score. As previously described, using the complex of a pyrimidine derivative with 
PLK1, Lidaeus was employed to dock approximately 200,000 commercially available small molecules. 
From these, 350 in silico ranked compounds were assayed for PLK1 inhibition in a radioactive kinase assay 
quantifying the amount of radio-labeled ATP incorporated into the Cdc25C substrate. A number of in vitro 
PLK1 inhibitors emerged from this strategy with an overall hit rate of 1% and a potency range of 0.5 to 20 
M IC50. While several confirmed hits were obtained, one series had more potent activity in the kinase 
assay and consisted of a benzothiazole N-oxide core structure. The obtained hit, 4 (Table 1) was promising 
not only from its sub-micromolar potency but also from its low molecular weight and potential for 
synthesizing a number of derivatives that could optimize potency and drug-like properties. The phenotypic 
activity of compound 4 has previously been described where novel roles of PLK1 in spindle pole 
maintenance were demonstrated through use of this molecule as a chemical biology probe(McInnes et al., 
 7 
2006). The structure-activity of 4 and its related analogs are described for the first time in the following 
results. 
 
  
 
Structure-activity relationship determination of benzothiazole inhibitors 
PLK1
CDK2/ 
cyclinE
Compound R1 R2 R3 R4
4 CF3 NO2 CONH2 O 2.47 ± 1.23 >100
5 F NO2 CONH2 O 18.1 ± 2.69 >100
6 I NO2 CONH2 O 0.36 ± 0.01 >100
7 COOCH3 NO2 CONH2 O 7.11 ± 0.86 >100
8 CN NO2 CONH2 O 8.4 ± 0.86 44.2 ± 3.18
9 CH3 NO2 CONH2 O >100 >100
10 SCF3 NO2 CONH2 O 0.39 ± 0.07 >100
11 COOH NO2 CONH2 O >100
12 CF3 NO2 CN O 17.0 ± 4.24
13 CF3 NO2 CONHOH O 31.0 ± 15.6 >100
14 CF3 NO2 CONH2 - >100
15 NO2 CF3 CONH2 O >100
16 CF3 NO2 CONHNH2 O >100
Structure Kinase inhibition (mM)
Table 1. Structure-activity relationships for the benzothiazole N -oxide PLK1 inhibitors
S
N
R4
R3
R2
R1
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Subsequent to the identification of 4 as a potent PLK1 inhibitor, a set of commercial compounds 
expanding on the benzothiazole N-oxide scaffold were obtained and tested for inhibition of PLK1. This 
included a significant number of secondary amide and ester derivatives at the R3 position of the thiazole 
ring. Surprisingly none of these compounds exhibited any significant level of in vitro inhibition of PLK1 
and thus suggesting an important contribution of the primary amide (see structure in table 1) to binding. 
In order to further explore the SAR of this series, a synthetic route for the benzothiazole N-oxide was 
developed and a number of analogues related to the in silico hit compound were prepared. Firstly, the 
substituents on the aryl component of the pharmacophore were modified and testing of these compounds in 
the PLK1 assay yielded information on the structure-activity relationship. A number of derivatives were 
synthesized (Table 1) replacing the CF3 with other groups and included fluoro 5, iodo 6, methyl ester 7, 
nitrile 8, and methyl 9. Surprisingly only compounds possessing electron-withdrawing substituents in this 
position exhibited activity against PLK1. In particular, the methyl group derivative 9, which is isosteric 
with CF3 was completely inactive. When the CF3 group in the in silico discovered compound was replaced 
with a trifluoromethyl-thioether 10, an increase in potency was observed. This compound increased in 
potency from 2.5 M to approximately 0.4 M suggesting that the spacing functionality resulted in more 
complementary interactions of the CF3 group in the ATP binding site. Generation of the free carboxylate 
group from hydrolysis of the methyl ester 7, to generate compound 11 interestingly resulted in an inactive 
molecule. 
Further synthetic modification of the substituents on the thiazole ring were carried out and revealed that 
the incorporation of other small polar groups replacing the amide resulted in active compounds although 
none as potent as the parent hit (Table 1). Compounds tested included those with nitrile 12, hydroxamate 
13 and hydrazide 16 functions. An additional observation made was that closely related compounds lacking 
the N-oxide on the thiazole ring were completely devoid of activity as exemplified by the reduction of the 
N-oxide in 4 to generate 14 and that of the reduction of 10 to its counterpart (data not shown). These results 
were not in line with the predicted small contribution of a single atom to intermolecular binding but pointed 
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to the importance of the electrostatic nature and electron-withdrawing potential of the N-oxide functionality. 
Further SAR for the benzothiazole N-
oxide series was established through 
the synthesis of compound 15 with the 
CF3 and nitro groups reversed. This 
compound was surprisingly inactive 
pointing to essential interactions of 
the nitro group with the ATP binding 
site of PLK1. 
Figure 3. Molecular docking of 
the in silico discovered benzothiazole 
N-oxide, 4 with the ATP binding site 
of PLK1. The binding mode was 
predicted based on most favourable 
interaction energies and the SAR of 
the primary amide group thus 
consistent with hinge H-bonding interactions. The displayed pose is consistent with the Meisenheimer 
hypothesis requiring the proximity of the benzothiazole C4 to the attacking thiol nucleophile from C67.  
 
In order to gain some insight into the binding of the benzothiazole N-oxide lead compounds in the PLK1 
ATP cleft and to assess the contributions of various substituents for binding, molecular docking experiments 
were carried out using the PLK1 model structure and subsequently with the available crystal structures. 
Using this approach, numerous docking solutions are evaluated in terms of interaction energy, docking 
score and with respect to consistency with known kinase inhibitory interactions. Particular attention was 
paid to the observed requirement for a primary amide group on the thiazole. A binding mode that fulfilled 
each of these criteria was observed (Figure 3). Interestingly, C67 is in close proximity to the aromatic ring 
of the benzothiazole although does not make the complementarity expected from the valine residue that is 
commonly found in this position. In addition, the interactions observed in the docked structure provided a 
clear rationale for CF3S group. These calculations indicate that the CF3S projects into a subpocket and 
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shows a high degree of complementarity with this region. A good correlation was observed between the 
non-bonded docking score and the potency of the inhibitors.  
 
Benzothiazole N-oxide inhibitors interact covalently with the PLK1 active site. 
In order to confirm that the benzothiazoles were binding to the ATP cleft of PLK1 and were not targeting 
substrate binding or possibly another site resulting in allosteric inhibition of ATP binding, the Km, ATP was 
determined at various inhibitor concentrations.  This measurement was repeated for two of the most potent 
PLK1 inhibitory compounds, 4 and 10. While compound 4 (2.5 M IC50) was shown to be ATP competitive 
as evidenced by the variation in the Km for ATP, the significantly more potent analogue, 10 was found to 
have similar Km for ATP at every ligand concentration studied (Figure 4). These data indicate that the 
equilibrium of binding for compound 10 shifts towards being non-ATP competitive in contrast to inhibitor 
4. In light of these results, observation of the C67 sidechain in the PLK1 model structure and the outcomes 
of using thiol modifying agents, it was hypothesized that these compounds may be interacting covalently 
with the cysteine. Further investigation into the chemistry of the benzothiazole N-oxide series suggested a 
literature precedent for reactivity and susceptibility to nucleophilic attack on the aromatic ring (Bunting, 
1979). This reaction has been shown to occur ortho or para to a nitro substituted phenyl ring where a 
covalent intermediate is formed per the mechanism shown above Table 2. and has been named the 
“Meisenheimer complex”.   
Examination of the docked structure of 4 with the PLK1 model structure indicates a close proximity of 
the thiol of C67 and the C4 aromatic carbon (para to the nitro group and highlighted in Figure 3) and hence 
strongly supports this hypothesis. Confirmation of the Meisenheimer complex was indicated though a set 
of model 1H NMR experiments with the active and inactive compounds from the benzothiazole series. 
Addition of n-butylamine as a surrogate nucleophile to the active compounds including 4, 7, 8 and 10, in 
each case, resulted in a dramatic colour change of the compound in solution. For solubility purposes, all of 
these experiments relied on the use of the ethyl ester derivatives of each benzothiazole (R3 = CO2Et) 
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dissolved in deuterated chloroform and therefore the majority of model reactions were carried out using n-
butylamine. Experiments were also undertaken with sodium 1-butanethiolate and showed similar dramatic 
changes in the color of the compound solution and in the UV spectrum (Supplementary figures 1 and 2). 
The requirement for non-polar aprotic NMR solvents (potentially reactive) to solubilize the 1-butanethiolate 
precluded NMR experiments with this more appropriate model nucleophile. Use of more polar solvents did 
not allow NMR study of the Meisenheimer complex due to lack of compound solubility.  
Further experiments utilizing UV/Vis spectrophotometry were carried out to support this hypothesis 
using ethanol as the solvent of choice. During initial experiments to identify the presence of the 
Meisenheimer complex, it was observed that highly colored solutions were obtained upon addition of the 
model nucleophile (n-butylamine) to the benzothiazole N-oxide inhibitor, an observation consistent with 
the literature where a red shift in the UV/Vis spectrum is seen for the max (Taylor, 1970). An extensive 
UV/Vis spectrophotometric characterization of the series of active and inactive benzothiazoles was 
subsequently carried out to examine if a relationship existed between the induced color change and potency 
of the pharmacophoric series (Table 2). It was determined that for each of the active PLK1 inhibitors from 
this series, a substantial shift in UV absorbance was identified accompanied by a dramatic increase in 
extinction coefficient for the new signal.  Out of 8 compounds tested, all 6 analogues with measurable IC50’s 
against PLK1 exhibited a significant UV shift and an enhancement of extent of absorbance. Conversely, 
neither of the inactive molecules in the series displayed either a UV shift or an increase in extinction 
coefficient (9a and 11a). In addition, a rough correlation of the increase in absorbance and potency of the 
compounds can be extracted from the measured data. Furthermore 2 additional inactive compounds in this 
series were tested and no UV shift or absorbance increase was observed (data not shown).  
Further characterisation of the 1H NMR spectra of the inhibitors before and after addition of the 
nucleophile (n-butylamine) resulted in a disappearance of both the aromatic protons in the spectrum (Table 
2) and a shift of the signals further upfield, which is characteristic of the cyclohexa-2,5-dien-1-ylidene 
azinate structure formed after nucleophilic attack (see above Table 2). Subsequent examination of the 
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inactive compounds in a similar experimental protocol determined that for these benzothiazoles, no change 
in the aromatic 1H NMR signals occurred. This was shown to be true for the previous incongruously inactive 
compounds including the CF3 to CH3 replacement, 9 and the carboxylate derivative, 11. Analysis of the 
compounds (those active against PLK1) recovered after removal of the n-butylamine showed that there was 
no evidence of the Meisenheimer adduct therefore confirming that this is a fully reversible reaction. 
 
Activity of compound 4 and Volasertib (BI6727) against PLK1 WT and PLK1 C67S 
In order to confirm whether C67 plays a role in the activity of the benzothiazole N-oxide series as 
strongly suggested by the SAR data, along with the enzyme kinetics and spectroscopy results, compound 4 
was investigated along with Volasertib (BI6727), a potent PLK1 ATP inhibitor currently FDA approved 
for the treatment of AML. Due to requirements for commercial assay screening, these compounds were 
tested against the wild-type PLK1 with a lower ATP concentration than previously used and shown to have 
IC50 values of 0.463 and 0.016 M respectively. Subsequent to this, a mutant PLK1 enzyme possessing the 
exchange of cysteine 67 for serine, was generated. As serine is considerably less nucleophilic than the native 
cysteine residue, it would not be expected to form the Meisenheimer complex to a significant degree and 
therefore the activity of the benzothiazole N-oxide series should be dramatically lower in the context of this 
mutant. Testing of volasertib in the first instance showed that while its activity against PLK1 C67S was 
reduced compared to the wild type, an IC50 of 0.151 M was obtained (Figure 5). Staurosporine was also 
shown to potently inhibit PLK1 C67S (Supplementary Figure 3). This contrasted to compound 4 which was 
found to be completely inactive at concentrations of >100 M thereby providing confirmation that Cys67 
forms a covalent Meisenheimer complex with the benzothiazole N-oxide series as strongly suggested by 
the previously described data. 
 
Kinase Selectivity and Cellular activity of lead inhibitors 
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Since specificity can be problematic in the development of ATP competitive inhibitors of any protein 
kinase, the benzothiazole N-oxide series was tested on a panel of in house enzymes (Table S1). Interestingly 
none of these were inhibited by the in silico identified lead compound 4. In order to further probe the 
selectivity of this compound, a further 20 kinases available from an out-sourced screen were examined for 
inhibition in the presence of 100 M of 4 and included 3 kinases with a cysteine in the position equivalent 
to PLK1 (Table S2). None of this additional panel exhibited a significant level of inhibition with the 
exception of CSK whose activity was slightly blocked by the action of this compound (<50% inhibition at 
100 µM compound). Due to the potency obtained for fragment like series and the high degree of selectivity 
observed, it is apparent that the specificity arises from the demonstrated mechanism of inhibition through 
the MC. The selectivity of the most potent inhibitor, 10 was also examined by testing against an in-house 
kinase panel and confirmed its selectivity towards PLK1. 
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Figure 4.  Enzyme kinetics of benzothiazole PLK1 Inhibitors. Lineweaver Burk Plot analysis of compounds 
4 and 10 suggest that they act via competitive (A) and non-competitive (B) binding respectively. (C). The 
ATP dependence of these two inhibitors further confirms this analysis (compound 4 with red data points 
and 10 in magenta).  
 
DISCUSSION 
The results presented here demonstrate that an approach to generating PLK1 inhibitors involving 
homology modeling, molecular docking of known ligands and in vitro testing has determined novel features 
of the PLK1 ATP binding site that can be exploited in the structure guided design of compounds specific 
for this kinase. The ability to 
selectively inhibit PLK1 via 
covalent interaction with C67 of 
the ATP binding  
site was confirmed through the 
synthesis of thio-adenosine 
derivatives (1, 2). The cysteine is located on the glycine-rich loop in the N-lobe region in the position 
occupied by a valine in the majority of protein kinases and is quite unique to the Polo-like kinases. The 
Table 2 Spectroscopic results of benzothiazole N -oxide Meisenheimer formation (in the presence of n -BuNH2)
4a CF3 2.47 ± 1.23 9.00-8.99 8.85-8.84 6.78-6.77 6.61 405, 5369 440, 24832
5a F 18.1 ± 2.69 - - - - 380, 3143 450, 7429
6a I 0.36 ± 0.01 8.94 8.81 - - 410, 3937 465, 12992
7a COOCH3 7.11 ± 0.86 8.96 8.81 7.10 7.00 400, 2443 420, 19870
8a CN 8.4 ± 0.86 - - - - 410, 4399 450, 14076
9a CH3 >100 8.65 8.42 8.70-8.40 8.70-8.40 400, 5085 395, 5367
10a SCF3 0.39 ± 0.07 8.93 8.78 6.78 6.64 405, 4412 445, 18382
11a COOH >100 8.96 8.80 9.00 8.82 395, 4063 390, 4375
b 
all 
1
H NMR performed in CDCl3 
c
 all UV/Vis in EtOH
dAr1 (ppm)
b                     
+ n -BuNH2
dAr2 (ppm)
b                     
+ n- BuNH2
a
 primary amide of R3 is replaced by COOEt
R1
lmax (nm), e         
(L mol
-1
 cm
-1
)
c
lmax (nm), e                    
(L mol
-1
 cm
-1
)
c                     
+ n- BuNH2
Compound
Plk1 activity 
(mM) when R3 
= CONH2
dAr1 (ppm)
b 
dAr2 (ppm)
b
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preferential inhibition of PLK1 by 5TA, 2 which according to known kinase-ATP structures and subsequent 
modeling (Figure 2) in the PLK1 context results from proximity of the thiol group to the reactive cysteine 
(as opposed to 2’-thio derivative where the thiol group projects towards the C-lobe and therefore would be 
less able to react with C67). Although 2TA, 1 inhibits PLK1 to a certain degree, its observed activity 
probably results from the flexibility of the ribose in the ATP binding site, enabling reaction with the cysteine 
residue. In addition, the observation that adenosine does not inhibit PLK1 gives weight to the hypothesis 
that selective covalently interacting inhibitors can be designed and synthesized based on the structural 
information obtained from this approach. These results taken as a whole, strongly suggest that the cysteine 
residue present in the PLK1 ATP cleft can form covalent interactions with appropriately positioned 
electrophilic groups in an inhibitor. This novel feature of PLK1 should thus enable the discovery and design 
of inhibitors that potently and selectively inhibit the activity of Polo-like kinases. To this end, as the 
homology structure was extensively validated, it was confidently utilized for database searching for new 
PLK1 inhibitors and resulted in the identification of the benzothiazole N-oxide pharmacophore. Results 
show that potency and selectivity for PLK1 over many other kinases can be achieved through this chemical 
series, which not only binds avidly to the active site but also interacts covalently with C67. While the 
homology structure was used in initial studies to propose the covalent mechanism of inhibition and for 
discovery of the benzothiazole N-oxide inhibitors, the publication of multiple crystal structures of the PLK1 
kinase domain confirmed the position of C67 and further validated the results obtained with the homology 
structure. Furthermore, compounds were redocked with PLK1 crystal structures and as expected also found 
to have binding modes compatible with formation of the Meisenheimer complex. 
It is apparent from these results that the necessity for an electron withdrawing group on the phenyl 
substituent of the benzothiazole and the presence of the N-oxide for PLK1 inhibition relate to the ability of 
these compounds to form Meiseheimer complexes. This was determined by demonstrating a correlation 
between inhibitors of the benzothiazole series that show activity against PLK1 and their ability to induce 
spectroscopic changes upon addition of a model nucleophile. This was further supported by the requirement 
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of the R1 position (see Table 1) to be an electron withdrawing substituent. Small changes in the chemical 
structure of this series (i.e. replacement with isosteric groups e.g. CF3 to CH3 or removal of the N-oxide 
functionality) which should not be so detrimental to kinase activity, resulted in complete lack of PLK1 
inhibition. These changes do not significantly alter the steric nature of the inhibitor but would dramatically 
change the electronic nature of the structures. Increasing the electron-withdrawing character at R1 would 
therefore make the C4 and C6 positions of the nitro-substituted benzothiazole ring, less electron-rich and 
more susceptible to nucleophilic attack, resulting in formation of the MC (see above Table 2). This was 
corroborated by the observed correlations that exist between the electronegativity of the R1 and R2 groups 
and the inhibitor potency, and also between the UV absorbance of the Meisenheimer adduct and the PLK1 
activity.  
The higher potency of compound 10 and the differing kinetics vs. 4 (Figure 4.) can be explained by the 
greater affinity and complementarity of SCF3 group with the PLK1 ATP binding site the structural basis 
for this potency increase has been determined computationally. It is known that the SCF3 group has almost 
twice the lipophilicity of the CF3 group and therefore has greater potential to interact through van der Waals 
interactions in a binding pocket(Feng et al., 2016). Calculations show that the SCF3 of 10 has a significantly 
higher degree of complementarity with a sub pocket of the ATP binding site compared to the CF3 (4), 
occupying it almost completely and therefore explaining the potency increase in these terms alone (The 
significantly increased interactions of the SCF3 group are shown comparatively, supplementary figure 4). 
As a result of these increased interactions and consistent with known enzyme inhibition kinetics, it known 
that if the affinity is tight enough, compounds can display non-competitive behavior. The kinetic differences 
of 4 vs 10 can be accounted for by the increased potency of 10 which results in stabilization of the binding 
mode and therefore by extension, the covalent Meisenheimer complex (Table 1).  Other explanations such 
as displacement of the SCF3 group or differences in the oxidation of the two compounds are very unlikely 
due to the similar electronegativities of the CF3 and SCF3 group and also the restrictions on the SNAr 
reaction in this system.   
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The lack of inhibition of the carboxylate derivative 11, despite possessing an electron withdrawing 
substituent most probably results from delocalization of the negative charge into the aromatic ring thus 
disfavoring nucleophilic attack. This was supported by the observation that this compound was refractory 
to formation of the MC as evidenced by the described spectroscopic methods. Reversal of the CF3 and NO2 
groups of 4 to generate compound 15, resulted in complete loss of activity on PLK1, an effect probably due 
to the critical nature of the nitro function to direct binding and supported by electrostatic interactions with 
K82 in the docked structures (Figure 3). Since the nitro group is acting as an electron sink it will be more 
negatively charged in the MC and therefore contributes significantly to the enthalpy of binding.  
 
Figure 5.  Comparison of the activities of compound 4 (left) and Volasertib (right) against PLK1 C67S, a 
mutant designed to test the contributions to C67 to the activity of the benzothiazole N-oxide series. The data 
obtained for the replacement of the cysteine with a serine, an isosteric residue and which is considerably 
less nucleophilic, confirms the formation of the Meisenheimer complex with 4.  
 
Confirmation for the Meisenheimer complex formation and the resulting covalent inhibition of PLK1 
through C67 was obtained through comparison of the activities of compound 4 and Volasertib (BI6727) in 
inhibiting the wild-type PLK1 vs. the C67S mutant. The retention of potent activity of Volasertib for the 
mutant PLK1 and the complete loss of inhibition of 4 in this context provides strong evidence that the 
benzothiazole N-oxide series act through Meisenheimer complex formation. The decreased activity of 
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Volasertib with PLK1 C67S is most likely due to the loss of van der Waals contacts in the context of the 
serine as the oxygen has a significantly smaller atomic radius than the sulfur.  
The formation of the Meisenheimer adduct between the benzothiazole ring and the sulfur nucleophile 
leads to high affinity binding of this series and is almost certainly responsible for the selectivity for PLK1 
vs. all of the other enzymes tested. This method of kinase inhibition is currently without precedent in the 
literature and has been demonstrated to be a paradigm through which selective kinase inhibitors can be 
obtained. Despite the observation that these act through covalent bond formation with the reactive cysteine 
in the PLK1 active site, this series should not suffer from reactivity with general nucleophilic groups in 
biological milieu since the Meisenheimer complex is not a stable intermediate and is under normal 
conditions fully reversible. This was demonstrated in the context of the benzothiazole N-oxide series in that 
no stable intermediate Meisenheimer complex could be isolated after addition of model nucleophiles even 
though the presence of this species was confirmed using two spectroscopic methods.   
In addition to the experimental methods used and which confirmed the mechanism of inhibition of the 
benzothiazole series through the MC, the molecular docking calculations that were carried out, strongly 
support the proposed covalent interaction with C67. The binding modes and interaction energetics generated 
using a rigorous molecular mechanics docking approach (allowing flexibility of both the ligand and ATP 
binding site residues) were predicted for a set of the active analogues. As the SAR data pointed to the critical 
nature of the primary amide group, and since a frequent binding determinant of kinase inhibitors includes 
an H-bond donor and acceptor pair to the interdomain connecting loop (“hinge”), it is highly probable that 
the amide is responsible for these interactions (no other H-bond donors in the parent benzothiazole 
molecule, 4). Docking of other active isosteres at this position including the nitrile 12, hydroxamate 13 and 
the hydrazide 16 derivatives confirm the contributions of the hinge contacts and therefore the overall 
binding mode. Overall an excellent correlation between the interaction energy of this series of benzothiazole  
N-oxide derivatives and the IC50 values was observed and therefore confirms the binding mode that 
positions C67 for nucleophilic attack to form the Meisenheimer complex.  
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A study has demonstrated that potent and selective inhibitors of protein kinases could be obtained using 
a structural bioinformatics approach that targeted the corresponding cysteine described in this work as 
resulting in specific PLK1 inhibition(Cohen et al., 2005). Sequence alignment analysis revealed that eight 
other protein kinases have the equivalent cysteine residue representing 4 different kinase families. In this 
example, however, in addition to cysteine, a threonine “gatekeeper” was required in order to provide 
additional space for a substituent on the designed inhibitor. While 3 of these kinases (MSK2, NEK2 and 
RSK1) were probed for inhibition by compound 4 and 10 and no significant activity observed, each could 
potentially be inhibited by appropriate tuning of the inhibitor containing a “Meisenheimer Complex 
Scaffold”. Furthermore, recent work described the analysis of cysteine residues across the human kinome 
and which would be available for covalent inhibitor development(Zhao et al., 2017). This study concluded 
that there are 44 kinases containing cysteine residues that have been successfully exploited by covalent 
kinase inhibitors. There is therefore a plethora of potential kinase drug targets that the Meisenheimer 
complex approach could be applied to for potent and selective inhibition. While resistance through mutation 
of the cysteine residue is always possible, it remains so regardless of the mode of covalent inhibition. 
In summary through study of the PLK1 kinase domain, unique features of its ATP binding site have 
been exploited in the discovery and design of inhibitors. A class of PLK1 inhibitors based on the 
benzothiazole N-oxide have been described and shown to selectively inhibit the enzyme through a 
Meisenheimer complex, a mechanism of action not previously described for protein kinase inhibitors. This 
pharmacophore represents a prototype for a new approach to generate PLK1 inhibitors and in fact inhibitors 
in general that possess high selectivity through reversible covalent interaction. Such inhibitors have the 
potential added benefit of minimizing off target effects that occur with irreversible inhibitors.  
 
SIGNIFICANCE  
The polo family of mitotic kinases are clinically validated oncology targets. Structure based discovery and 
design has led to a class of inhibitors of PLK1 catalytic activity that covalently interact with C67 of the ATP 
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binding site. Benzothiazole N-oxide derivatives reversibly inhibit PLK1 through the formation of 
Meisenheimer complexes, a mechanism of kinase inhibition which yields high selectivity while avoiding 
off target effects that occur through covalent binding to other thiol containing molecules in the cell. Due to 
recent renewed interest in covalently binding inhibitors as a class of drugs and the plethora of targets that 
can be inhibited using this approach, these compounds represent prototypes for the design of kinase 
inhibitors and in fact inhibitors in general that exploit the Meisenheimer complex to generate potent and 
selective compounds that potentially also avoid toxicity issues arising for irreversibly binding drugs.  
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STAR METHODS  
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the Lead Contact, Campbell McInnes (mcinnes@cop.sc.edu). 
 
 
METHOD DETAILS 
 
General method for the synthesis of 2-alkoxycarbonyl-N-oxide derivatives 
See Supplementary Figure 5 for synthetic scheme (McInnes et al., 2006). Step 1: Triethylamine (1.1eq) was 
added to a suspension of 5 substituted, 1,3-dinitrobenzyl-2-chloride (1eq) and ethyl thioglycolate (1eq) in 
ethanol (3cm3) at 10-20C (Scheme 1). Onset of the reaction was observed by the solvent beginning to 
reflux even though the mixture was being cooled in a water bath. After stirring for a further 3h a precipitate 
formed which was collected by filtration, washed with ice-cold water followed by a further wash with ice-
cold methanol. Recrystallization from methanol gave the desired ethyl ester derivatives. Step 2: The 2-
alkoxycarbonylbenzothiazol-3-oxide (1eq) was suspended in ethanol (2 cm3) at 20-30C and ammonium 
hydroxide (1.2eq) added. After stirring for 4h, the desired 2-carbamoyl benzthiazol-3-oxide crystallised 
from solution, was collected by filtration and was washed with ice-cold water and then methanol. 
Recrystallisation from methanol gave the desired amide derivatives. For further information see  McInnes 
et al., 2006. 
 
Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide, compound 4 
The general method above was followed using 2-chloro-5-trifluoromethyl-1,3-dinitrobenzene. The title 
compound was obtained as a yellow crystalline solid: 1H NMR (DMSO-d6, 500 MHz): H 8.76 (2H, s, Ar-
H and NH), 8.96 (1H, s, Ar-H) and 9.36 (1H, s, NH). MS (ESI+) m/z 308.01 [M+H]+ (C9H5N3O4F3S requires 
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308.00). mp 222-223C (lit 225-226C, Wagner et al., 1973). Anal. RP-HPLC: tR 13.75 min. (10-70% 
MeCN). 
Synthesis of  4-Fluoro-2,6-dinitrophenyl 4-methylbenzenesulfonate, precursor for compound 5 
4-Fluoro-2,6-dinitrophenol (1eq) was dissolved in toluene (5cm3) and tosyl chloride (1.1eq) added followed 
by pyridine (1.1eq) (Supplementary Figure 6). After stirring for 12h a white precipitate formed which was 
collected by filtration. The mother liquor was evaporated to dryness and used without further purification. 
1H NMR (DMSO-d6, 500 MHz): H 2.48 (3H, s, CH3), 7.50 (2H, d, J 8.0, 2 x Ar-H), 7.67 (2H, d, J 8.0, 2 x 
Ar-H) and 8.51 (2H, d, J 8.0, 2 x Ar-H). 
 
Synthesis of 2-Carbamoyl-5-fluoro-7-nitrobenzothiazole 3-oxide, compound 5 
The title compound was obtained as a yellow crystalline solid from 4-fluoro-2,6-dinitrophenyl 4-
methylbenzenesulfonate using the general method for the synthesis of 2-alkoxycarbonyl-N-oxides. 1H NMR 
(DMSO-d6, 500 MHz): H 8.82 (1H, s, NH), 8.88 (1H, d, J 7.5, Ar-H), 8.97 (1H, d, J 7.5, Ar-H) and 9.41 
(1H, s, NH). C8H5N3O4FS requires M 257.99848, found 257.99861. mp 282-283C. Anal. RP-HPLC: tR 
9.83 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-5-iodo-7-nitrobenzothiazole 3-oxide, compound 6 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-iodo-1,3-dinitrobenzene 
using the general method. 1H NMR (DMSO-d6, 500 MHz): H 8.81 (1H, s, Ar-H), 8.82 (1H, s, NH), 8.94 
(1H, s, Ar-H), and 9.41 (1H, s, NH). C8H4N3O4IS requires M 364.89673, found 364.89634. 
 
Synthesis of 2-carbamoyl-5-(methoxycarbonyl)-7-nitrobenzothiazole 3-oxide, compound 7 
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The title compound was obtained as a yellow crystalline solid from 2-chloro-5-methoxycarbonyl-1,3-
dinitrobenzene using the general method. 1H NMR (DMSO-d6, 300 MHz): δH 3.89 (3H, s, CH3), 8.78 
(4H, s, 2 Ar-H and 2 NH).  
 
 
Synthesis of 2-Carbamoyl-5-cyano-7-nitrobenzothiazole 3-oxide, compound 8 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-cyano-1,3-dinitrobenzene 
using the general method. 1H NMR (DMSO-d6, 500 MHz): H 8.86 (1H, s, NH), 9.16 (1H, s, Ar-H), 9.22 
(1H, s, Ar-H) and 9.33 (1H, s, NH). C9H4N4O4S requires M 263.9953, found 263.9951. mp 222-223C (lit 
225-226C, Wagner and Oehlmann., 1976), Anal. RP-HPLC: tR 19.60 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-5-methyl-7-nitrobenzothiazole 3-oxide , compound 9 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-methyl-1,3-dinitrobenzene 
using the general method. mp 271-272C (lit 274-275C, Wagner et al., 1973). Anal. RP-HPLC: tR 11.32 
min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-7-nitro-5-((trifluoromethyl)thio)benzothiazole 3-oxide, compound 10 
The title compound was obtained as a yellow crystalline solid from 2-chloro-5-(trifluoromethylthio)-1,3-
dinitrobenzene using the general method. 1H NMR (DMSO-d6, 500 MHz): H 8.82 (1H, s, Ar-H), 8.85 (1H, 
s, Ar-H), 8.90 (1H, s, NH) and 9.35 (1H, s, NH). C9H5N3O4F3S2 requires M 339.96736, found 339.96739. 
mp 255-256C, Anal. RP-HPLC: tR 15.79 min. (10-70% MeCN).  
 
Synthesis of 2-Carbamoyl-5-carboxy-7-nitrobenzothiazole 3-oxide, compound 11 
Compound 7 (26mg, 0.09mmol) was suspended in water (1.0ml) containing methanol (0.1ml). Sodium 
hydroxide (4mg, 0.1mmol) in water (0.36ml) was added and the resultant precipitate collected by filtration 
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and washed with water.  The title compound was obtained as a yellow crystalline solid, 1H NMR (DMSO-
d6, 500 MHz): H 7.88 (1H, s, Ar-H) and 8.35 (1H, s, Ar-H), C9H5N3O6S requires M 282.9899, found 
282.9900. mp 181-183°C (lit 188-190°C, Wagner et al., 1973), tR 16.38 min. (10-70% MeCN). 
 
Synthesis of 2-Cyano-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , compound 12 
Phosphorus oxychloride (306mg, 0.186ml, 2.0mmol) was added to a suspension of 4 (672mg, 2.0 mmol) 
in dry pyridine (1ml) at 20-30C and stirred for 12h (Wagner and Oehlmann., 1976). Ice-water was added 
and the resultant precipitate collected by filtration. The title compound was obtained as a yellow crystalline 
solid. 1H NMR (DMSO-d6, 500 MHz): H 8.91 (1H, s, Ar-H) and 9.02 (1H, s, Ar-H). mp 188-189°C (lit 
190-191°C, Wagner et al., 1973), tR 15.60 min. (10-70% MeCN). 
 
Synthesis of 2-(Hydroxycarbamoyl)-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , compound 13 
The title compound was obtained as a yellow crystalline solid from the reaction of compound 4 with 
hydroxylamine using routine methodology (Wagner et al., 1973). 1H NMR (DMSO-d6, 500 MHz): H 8.86 
(1H, s, Ar-H), 8.96 (1H, s, Ar-H), 10.17 and 12.13 (2H, s, NH and OH). MS (ESI+) m/z 346.00 [M+Na]+ 
and 324.07 [M+H]+ (C9H4N3O5F3S requires 322.98). mp 230-231C (lit 234-235C, Wagner et al., 1973). 
Anal. RP-HPLC: tR 12.33 min. (10-70% MeCN). 
 
Synthesis of 2-Carbamoyl-7-nitro-5-(trifluoromethyl)benzothiazole , compound 14 
Compound 4 (30mg, 0.097 mmol) was dissolved in ethanol (2ml) and heated to 70C. Triethyl phosphine 
(17mg, 1.1eq) was added and the mixture remained at 70C for a further 4h. On cooling the resultant 
precipitate was collected by filtration. The title compound was obtained as a yellow crystalline solid: 1H 
NMR (DMSO-d6, 500 MHz): H 8.36 (1H, s, NH), 8.68 (1H, s, NH), 8.77 (1H, s, Ar-H) and 8.92 (1H, s, 
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Ar-H).  mp 222-224C (lit 225-226C, Wagner and Oehlmann., 1976). Anal. RP-HPLC: tR 16.01 min. (10-
70% MeCN).  
 
Synthesis of 2-Carbamoyl-5-nitro-7-(trifluoromethyl)benzothiazole 3-oxide , compound 15 
The title compound was obtained as a yellow crystalline solid from 2-chloro-1,5-dinitro-3-
(trifluoromethyl)benzene using the general method. 1H NMR (DMSO-d6, 500 MHz): H 8.88 (1H, s, Ar-
H), 8.90 (1H, s, NH), 8.97 (1H, s, Ar-H) and 9.33 (1H, s, NH), C9H4F3N3O4S requires M 306.9875, found 
306.9880. mp 224-225C (lit 225-226C, Wagner et al., 1973). 
 
Synthesis of 2-(Hydrazinecarbonyl)-7-nitro-5-(trifluoromethyl)benzothiazole 3-oxide , compound 16 
The title compound was obtained as a yellow crystalline solid from the reaction of compound 4 with 
hydrazine using standard procedures (Wagner et al., 1973). 1H NMR (DMSO-d6, 500 MHz): H 5.20 (2H, 
s, NH2), 8.88 (1H, s, Ar-H), 8.95 (1H, s, Ar-H) and 11.20 (1H, s, NH). mp 229-230C (lit 232-233C, 
Wagner et al., 1973). Anal. RP-HPLC: tR 11.88 min. (10-70% MeCN). 
 
Expression and purification of Plk1 for kinase assays. 
The Plk1 open reading frame (X75932) was amplified from a fetal lung complementary DNA library 
(Clontech) using primers incorporating restriction enzyme sites. The 5′ primer (5′-
GCCGCTAGCGACGATGACGATAAGATGAGTGCTGCAGTGACTGCAGGGAAGC-3′) had an NheI 
site upstream of the ATG start codon. The 3′ primer (5′-GGAATTCTTAGGAGGCCTTGAGACGG-3′) 
incorporated an EcoRI site downstream of the stop codon. The PCR product was subcloned into the 
NheI/EcoRI sites of a baculovirus expression vector (pSSP1) derived from pFastBac Hta (Invitrogen). 
Cloning into this vector resulted in a hexahistidine-tag fusion at the N terminus of the Plk1 construct. Sf9 
strain cells of a passage number less than 20 were split back to give a 300-ml culture volume, at a cell 
density of 1.5 × 106 cells ml−1. Cells were only used for expression in logarithmic growth phase. Plk1 
 30 
baculovirus (from P2 amplification) was added to give a multiplicity of infection of 3; this is equivalent to 
three virus particles for each insect cell. The flasks were incubated at 27 °C, with shaking at 100 r.p.m., for 
48 h. On harvest, cell density and viability were determined, and the cultures were spun down at 2,500 
r.p.m. for 5 min and washed with ice-cold (0 °C) phosphate-buffered saline. The wash was re-spun at the 
same speed and the pellet was snap frozen. Plk1 protein was purified on a metal affinity column. The insect 
cell pellet was lysed in a buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, 1 mM 
PMSF, 1 mM benzamidine, 20 mM imidazole and protease inhibitor cocktail (Sigma)) and the precleared 
supernatant was loaded onto Ni-NTA-agarose (Qiagen). The affinity column was washed with the lysis 
buffer and the bound protein was eluted with 250 mM imidazole in the same buffer. After overnight dialysis 
against 25 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, protease 
inhibitor cocktail (Sigma) and 10% glycerol, the purified protein was stored at −70 °C until used. 
 
Construction, expression and purification of Cdc25C. 
Using standard techniques a full-length Cdc25C clone was isolated by PCR from HeLa mRNA and inserted 
on a BamHI-HindIII fragment into the plasmid pRsetA. The N-terminal Cdc25C fragment (encoding 
residues 1–300) was excised from this vector and inserted into the plasmid pET28a (between the NcoI and 
BamHI sites). Expression was under the control of the T7 promoter, and the encoded protein contains a 
hexahistidine tag at the C terminus. The vector was transformed into E. coli strain BRL(DE3) pLysS for 
expression experiments. The protein was expressed in BL21(DE3) RIL bacteria cells that were grown in 
LB medium at 37 °C until optical density at 600 nm of 0.6 was reached. Expression was induced with 1 
mM IPTG, and the bacterial culture was grown further for 3 h. The bacteria were harvested by centrifugation 
and the cell pellet resuspended in 50 mM Tris, pH 7.5, and 10% sucrose, flash frozen, and stored at −70 °C 
until used. Purification of the protein was then carried out by lysing the bacterial pellet in 10 ml of lysis 
buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol and 20mM imidazole) 
supplemented with a cocktail of protease inhibitors and sonicated six times at 20-s bursts. The lysate was 
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then centrifuged for 15 min at 15,000 r.p.m. and filtered through a 0.45-mm filter. The sample was then 
loaded onto a Ni-NTA agarose column and washed several times, and then the Cdc25 protein was eluted 
with a buffer containing 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM β-mercaptoethanol, 0.02% Nonidet 
P-40 (Calbiochem) and 250 mM imidazol. The eluate was then dialyzed, concentrated, snap frozen in liquid 
nitrogen and stored at −70 °C until used. 
 
Procedure for PLK1 Assay 
PLK1 kinase activity (compounds in Tables 1 and 2) was assayed using either Casein or the N-terminal 
domain of the human Cdc25C phosphatase (a natural substrate for PLK1) as substrates. The assays were 
carried out using a 96-well plate format by incubating Cdc25C (2 g/well) or Casein (50g/well) with 
varying concentrations of the Ni-NTA purified PLK1 and varying concentrations of the negative, non-
transformed host Sf9 cell lysate in a total volume of 25ul of 20 mM Tris/HCl buffer pH 7.0, supplemented 
with 25 mM -glycerophosphate, 5 mM EGTA, 1 mM DTT and 1 mM NaVO3. Reaction was initiated by 
the addition of 100 M ATP and 0.5 Ci of [-32P]-ATP. The reaction mixture was incubated at 30ºC for 1 
h, then stopped with 75 mM aq orthophosphoric acid, transferred onto a 96-well P81 filter plate (Whatman), 
dried, and the extent of Cdc25C phosphorylation was assessed by scintillation counting using a Packard 
TopCount plate reader.  
 
Cloning and Expression of PLK1 C67S. 
This was undertaken at BPS Bioscience (San Diego). After C67S mutation and C-terminal His tag were 
introduced by PCR, the insert was cloned into pFastBac vector (Thermo Fisher Scientific), followed by 
sequence analysis.  The plasmid was transformed into DH10Bac™ E. coli Competent Cells (Thermo Fisher 
Scientific) where it recombined with the parent bacmid to form an expression bacmid. The purified bacmid 
DNA was tested for recombination by PCR.  Then the bacmid DNA was transfected into insect cells for 
production of recombinant baculovirus particles. P3 virus was used for protein production. Protein was 
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expressed in Sf9 cells using recombinant baculovirus at a MOI of 3 grown in SF900II media (Gibco™).  
Cell were harvest by centrifugation three days after transfection and His tagged protein was purified using 
Ni-NTA affinity.  Briefly, cells were lysed by sonication after resuspension in TBS-T buffer.  Protein was 
purified using Ni2+-NTA agarose (Sigma) eluting with TBS-T buffer plus imidazole.  High purity elutions 
as assessed by SDS PAGE were pooled with glycerol and DTT added to a final concentration of 20% and 
3mM respectively.  Protein was quantified by Bradford reagent (Pierce™) using BSA as the standard.  
Purity was determined to be >90% by SDS PAGE.    
 
Procedure for PLK1 and PLK1 C67S Kinase Assay 
For the data shown in Figure 5, Supplementary Figure 3, the assay was performed by BPS Bioscience (San 
Diego) using Kinase-Glo Plus luminescence kinase assay kit (obtained from Promega). It measures kinase 
activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The 
luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated 
with the amount of kinase activity. The compounds were diluted in 10% DMSO and 5µl of the dilution was 
added to a 50µl reaction so that the final concentration of DMSO is 1% in all of reactions. All of the 
enzymatic reactions were conducted at 30 oC for 45 minutes for the wild type PLK1 and 60 min for 
PLK1(C67S). The 50µl reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 1 
mM DTT, 0.1 mg/ml PLK1 peptide substrate, 10 M (or 5 µM) ATP and PLK1 (Table 2.3.1). After the 
enzymatic reaction, 50 µl of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was added to 
each reaction and incubate the plate for 15 minutes at room temperature. The luminescence signal was 
measured using a BioTek Synergy 2 microplate reader 
Procedures for Molecular Modeling 
The homology model for PLK1 was generated using the program module Homology within the molecular 
modelling package InsightII (Accelrys, San Diego, CA) using PKA as a template structure. Compounds 
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were docked with the PLK1 homology model using the Affinity program within InsightII implementing a 
molecular dynamics docking routine. The binding site was defined as an 8 Å radius from the centre of a 
ligand placed in the ATP site. The calculation was performed using the CVFF force field in a two-step 
process and an implicitly derived solvation model and geometric H-bond restraints. Initially, the inhibitor 
was minimized into the ATP cleft, using a simple non-bonded method where the Coulombic and Van der 
Waals terms are scaled to zero and 0.1, respectively. The refinement phase involved molecular dynamics 
calculated over 5 ps in 100 fs stages, where the temperature was scaled from 500 K to 300 K followed by a 
final minimisation over 1,000 steps using the Polak-Ribiere Conjugate Gradient method. The docked 
structures were ranked energetically using the in-house developed programs Calsor and Calsorcont and the 
Ludi module of InsightII. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
PLK1 activity assays were performed in duplicate at each concentration. The luminescence data were 
analyzed using the computer software, Graphpad Prism. The difference between luminescence intensities 
in the absence of PLK1 (Lut) and in the presence of PLK1 (Luc) was defined as 100 % activity (Lut – Luc). 
Using luminescence signal (Lu) in the presence of the compound, % activity was calculated as: 
  
% activity = {(Lut - Lu)/(Lut - Luc)}×100%, where Lu= the luminescence intensity in the presence of the 
compound (all percent activities below zero were shown zero in the table).  
 
The values of % activity versus a series of compound concentrations were then plotted using non-linear 
regression analysis of Sigmoidal dose-response curve generated with the equation Y=B+(T-
B)/1+10((LogEC50-X)×Hill Slope), where Y=percent activity, B=minimum percent activity, T=maximum 
percent activity, X= logarithm of compound and Hill Slope=slope factor or Hill coefficient. The IC50 value 
was determined by the concentration causing a half-maximal percent activity. 
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The values of % activity versus a series of compound concentrations were then plotted using non-linear 
regression analysis of Sigmoidal dose-response curve generated with the equation Y=B+(T-
B)/1+10((LogEC50-X)×Hill Slope), where Y=percent activity, B=minimum percent activity, T=maximum 
percent activity, X= logarithm of compound and Hill Slope=slope factor or Hill coefficient. The IC50 value 
was determined by the concentration causing a half-maximal percent activity. 
 
 DATA AND SOFTWARE AVAILABILITY 
No data or software beyond what is included in this manuscript and supplementary information are 
available.  
 
